GU Cancers 2023 | Novel immunotherapeutic approaches under evaluation in patients with mCRPC

Russell Kent Pachynski, MD, Washington University School of Medicine, St. Louis, MO, discusses novel immunotherapeutic approaches under evaluation in patients with metastatic castration-resisitant porstate cancer (mCRPC), including vaccines with checkpoint inhibitors, CAR-T cell, bispecific antibodies and antibody-drug conjugates (ADCs). This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.